BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8800749)

  • 1. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II).
    Whitley CB; McIvor RS; Aronovich EL; Berry SA; Blazar BR; Burger SR; Kersey JH; King RA; Faras AJ; Latchaw RE; McCullough J; Pan D; Ramsay NK; Stroncek DF
    Hum Gene Ther; 1996 Mar; 7(4):537-49. PubMed ID: 8800749
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II).
    Braun SE; Pan D; Aronovich EL; Jonsson JJ; McIvor RS; Whitley CB
    Hum Gene Ther; 1996 Feb; 7(3):283-90. PubMed ID: 8835216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.
    Braun SE; Aronovich EL; Anderson RA; Crotty PL; McIvor RS; Whitley CB
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11830-4. PubMed ID: 8265633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II.
    Pan D; Shankar R; Stroncek DF; Whitley CB
    Hum Gene Ther; 1999 Nov; 10(17):2799-810. PubMed ID: 10584926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics and Gene Therapy in Hunter Disease.
    Sestito S; Falvo F; Scozzafava C; Apa R; Pensabene L; Bonapace G; Moricca MT; Concolino D
    Curr Gene Ther; 2018; 18(2):90-95. PubMed ID: 29618310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer.
    Di Francesco C; Cracco C; Tomanin R; Picci L; Ventura L; Zacchello E; Di Natale P; Anson DS; Hopwood JJ; Graham FL; Scarpa M
    Gene Ther; 1997 May; 4(5):442-8. PubMed ID: 9274721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome.
    Stroncek DF; Hubel A; Shankar RA; Burger SR; Pan D; McCullough J; Whitley CB
    Transfusion; 1999 Apr; 39(4):343-50. PubMed ID: 10220258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Supercharged Cells" for delivery of recombinant human iduronate-2-sulfatase.
    Pan D; Jonsson JJ; Braun SE; McIvor RS; Whitley CB
    Mol Genet Metab; 2000 Jul; 70(3):170-8. PubMed ID: 10924271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome.
    Hong Y; Yu SS; Kim JM; Lee K; Na YS; Whitley CB; Sugimoto Y; Kim S
    J Gene Med; 2003 Jan; 5(1):18-29. PubMed ID: 12516048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the iduronate-2-sulfatase gene in 12 Polish patients with mucopolysaccharidosis type II (Hunter syndrome).
    Popowska E; Rathmann M; Tylki-Szymanska A; Bunge S; Steglich C; Schwinger E; Gal A
    Hum Mutat; 1995; 5(1):97-100. PubMed ID: 7728156
    [No Abstract]   [Full Text] [Related]  

  • 14. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).
    Motas S; Haurigot V; Garcia M; Marcó S; Ribera A; Roca C; Sánchez X; Sánchez V; Molas M; Bertolin J; Maggioni L; León X; Ruberte J; Bosch F
    JCI Insight; 2016 Jun; 1(9):e86696. PubMed ID: 27699273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter syndrome (mucopolysaccharidosis type II) confirmed by in vitro mutagenesis and expression.
    Crotty PL; Braun SE; Anderson RA; Whitley CB
    Hum Mol Genet; 1992 Dec; 1(9):755-7. PubMed ID: 1284597
    [No Abstract]   [Full Text] [Related]  

  • 17. Freezing characteristics of genetically modified lymphocytes for the treatment of MPS II.
    Hubel A; Darr TB; Norman JA
    Cell Transplant; 1999; 8(5):521-30. PubMed ID: 10580346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iduronate sulfatase activity in serum, lymphocytes, and fibroblasts--simplified diagnosis of the Hunter syndrome.
    Liebaers I; Neufeld E
    Pediatr Res; 1976 Aug; 10(8):733-6. PubMed ID: 821034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate-2-sulfatase gene in Japanese patients.
    Sukegawa K; Tomatsu S; Fukao T; Iwata H; Song XQ; Yamada Y; Fukuda S; Isogai K; Orii T
    Hum Mutat; 1995; 6(2):136-43. PubMed ID: 7581397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.